CONCERO INC Reported Earnings

CONCERO INC (CERO) reported a loss of $0.54 per share on revenue of $0.00 million for the . .

CERo Therapeutics Holdings Inc. is an immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. The company's lead product candidate includes CER-1236. CERo Therapeutics Holdings Inc., formerly known as Phoenix Biotech Acquisition Corp., is based in OAKLAND, Calif.